Medication Guide App

Vincristine Liposome Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Acute Lymphoblastic Leukemia

2.25 mg/m2 intravenously over 1 hour every 7 days.

Renal Dose Adjustments

Data not available.

Liver Dose Adjustments

Data not available.

Dose Adjustments

The manufacturer suggests using caution when selecting a dose for elderly patients due to their greater frequency of decreased hepatic, renal, or cardiac function and concomitant disease or drug therapy.

The manufacturer recommends dose modifications for vincristine liposome related peripheral neuropathy. If the patient develops grade 3 or persistent grade 2 peripheral neuropathy, then interrupt therapy; discontinue if neuropathy remains at grade 3 or 4, and reduce dose to 2 mg/m2 if the neuropathy recovers to grade 1 or 2. If the patient has persistent grade 2 peripheral neuropathy following a dose reduction, then interrupt therapy for up to 7 days; discontinue if the neuropathy increases to grade 3 or 4, and reduce dose to 1.825 mg/m2 if neuropathy recovers to grade 1. If the patient has persistent grade 2 neuropathy after the second dose reduction, then interrupt therapy for up to 7 days; discontinue if the neuropathy increases to grade 3, and reduce the dose to 1.5 mg/m2 if the neuropathy recovers to grade 1.

Precautions

Vincristine liposome is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.

Vincristine liposome is only for intravenous use and can be fatal if administered by other routes. Intrathecal injection has led to death.

If extravasation occurs during administration, vincristine liposome should be discontinued immediately and treatment should be considered.

The manufacturer recommends verifying the drug name and dosage prior to preparation and administration of Vincristine liposome to avoid overdosage since it has different dosage recommendations than non-liposomal vincristine sulfate.

Since sensory and motor neuropathies are common and cumulative, patients should be monitored for symptoms of neuropathy before and during treatment. Neurological toxicity risk is greater in patients with preexisting neuromuscular disorders and if other neurologic toxic drugs are coadministered. If neuropathies worsen, the manufacturer recommends a delay, reduction, or discontinuation of vincristine liposome.

The manufacturer recommends monitoring complete blood counts prior to each dose of vincristine liposome, and to modify or reduce dose and administer supportive care if warranted.

Anticipate, monitor, and manage tumor lysis syndrome in patients with ALL (acute lymphoblastic leukemia).

Dose delay, reduction, or discontinuation of vincristine liposome may be necessary for severe fatigue.

Hepatic function tests should be monitored for elevated aspartate aminotransferase and liver toxicity. A reduction or interruption of vincristine liposome may be necessary.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).

Dialysis

Data not available.

Other Comments

Vincristine liposome should be refrigerated between 36 degrees to 46 degrees Fahrenheit (2 degrees to 8 degrees Celsius) and should not be frozen.

The manufacturer's product information should be consulted for complete reconstitution and dilution recommendations.

Hide
(web4)